Original news and analysis on international IP policy
Por David Cronin para Intellectual Property Watch Los miembros del Parlamento Europeo han decidido aplazar la aceptación del protocolo a un acuerdo de la Organización Mundial del Comercio en materia de patentes sobre medicamentos, a la espera de que los…
By David Cronin for Intellectual Property Watch Members of the European Parliament (MEPs) have voted to delay approval of a World Trade Organization agreement on patents for medicines, pending European Union governments giving greater political and financial support to poor…
By Tove Iren S. Gerhardsen A recent Organisation of Economic Cooperation and Development (OECD) high-level meeting on boosting the development of medicines for neglected diseases mainly found in developing countries, focused on a new model under which governments promise up-front…
By Tove Iren S. Gerhardsen NOORDWIJK, THE NETHERLANDS – Participants at a high-level meeting of the Organisation for Economic Cooperation and Development (OECD) meeting here informally agreed on an agenda for what needs to be done in the area of…
By Tove Iren S. Gerhardsen Side-events were held by a non-governmental organisation (NGO), an intergovernmental organisation and the Canadian competition authority last week alongside the negotiations for a Development Agenda at the World Intellectual Property Organization. They focused on implementation…
By Tatum Anderson for Intellectual Property Watch
A debate over how long to give exclusive rights over data submitted by pharmaceutical companies to governments in order to receive approval to sell a drug in their markets is controversial not only in India, but worldwide.
By Tatum Anderson for Intellectual Property Watch
When the Indian government published its report recently on yet another pharmaceutical patent-related issue predicted to split the industry, the Indian newspapers were divided as to whether brand name producers, generics producers or public health advocates had won.
The reason for the confusion is that the report is an exercise in appeasement, said Shamnad Basheer, a law professor at George Washington University Law School, and expert on this latest controversial subject, called data exclusivity, which is the rights drugs producers have over the data used to obtain marketing approval in a country.
By Tatum Anderson for Intellectual Property Watch The latest chapter in the Swiss pharmaceutical company Novartis’ challenge to the Indian intellectual property system begins on 18 June when the Indian Patent and Trademark Appellate Board (IPAB) is scheduled to hold…
By Tove Iren S. Gerhardsen World Intellectual Property Organization (WIPO) members this week are engaged in intensive negotiations on proposals to change WIPO’s activities and mandate to include more development issues. The Group B of developed countries, particularly the United…
By Tove Iren S. Gerhardsen The Group of Eight (G8) final declaration on “growth and responsibility” in Africa is being met with initial reactions from observers that it contains a weaker approach to address patents and medicines to ensure “universal…